EUVIMEDEUVIMED entdecken
Open Access

The β 2 ‐adrenoceptor agonist formoterol attenuates hallmarks of adrenal Cushing's syndrome

Kristan H Cleveland, Kyung-Soon Lee, Devasena Ponnalagu, Juan Jesus Vicente, Edward D Parker, Ji Yae Eunice Lee, Linda Wordeman, John D Scott

British Journal of Pharmacology · 2026-06 · 183 (11) · 3129-3145

DOI: 10.1111/bph.70370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 04.03.2026. Verfasst von Kristan H Cleveland und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Formoterol Fumarate, Cushing Syndrome, Adrenergic beta-2 Receptor Agonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS, NIH Diabetes, Obesity, and Metabolism program of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Signal transduction therapies aim to correct dysregulated cellular signalling pathways implicated in disease. Adrenal Cushing's syndrome, a disorder of excess cortisol production, is frequently driven by somatic mutations in protein kinase A catalytic subunits (PKAc), including PKAc L205R and PKAc W196R . Experimental Approach This study used a combination of in vitro adrenal cell models and an in vivo mouse model harbouring the PKAc W196R mutation to assess the effects of formoterol treatment on mitochondrial function, steroidogenic gene expression and cortisol production. Mitochondrial respiration was evaluated by Seahorse XF analysis and serial block face scanning electron microscopy, and protein expression was measured by western blot and immunohistochemistry. Key Results In this study, we demonstrate that the long‐acting β 2 ‐adrenoceptor agonist formoterol can be repurposed to manage hypercortisolism. Formoterol significantly attenuates corticosterone secretion in ATC7L adrenal cells expressing Cushing's‐associated PKAc variants. In a PKAc WT/W196R mouse model, formoterol treatment alleviates hypercortisolism without inducing adverse cardiovascular effects. Mechanistically, formoterol promotes nuclear translocation of PGC1α, leading to enhanced mitochondrial biogenesis and improved mitochondrial function, as confirmed by Seahorse metabolic analysis. Electron microscopy revealed increased mitochondrial number, volume and structural complexity in adrenal tissue. Analyses of patient samples and adrenal cell lines indicates that formoterol modulates the mitochondrial steroidogenic acute regulatory protein (StAR), suggesting a direct effect on steroidogenesis. Conclusion and Implications These findings support the therapeutic potential of formoterol as a new pharmacological strategy for treating Cushing's syndrome and its associated metabolic comorbidities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Formoterol FumarateCushing SyndromeAdrenergic beta-2 Receptor AgonistsAnimalsMiceMitochondriaHumansMaleCyclic AMP-Dependent Protein KinasesCell LineCorticosterone

Stichwörter der Autor:innen

Cushing's syndromeadrenal glandmitochondriaprotein kinase Aβ2‐adrenoceptor

Substanzen

Formoterol FumarateAdrenergic beta-2 Receptor AgonistsCyclic AMP-Dependent Protein KinasesCorticosterone

Autor:innen und Institutionen

  • Department of Pharmacology, University of Washington, Seattle, Washington, USA.
  • Department of Neurobiology and Biophysics, University of Washington, Seattle, Washington, USA.
  • Department of Opthamology, University of Washington, Seattle, Washington, USA.

Förderung

  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • NIH Diabetes, Obesity, and Metabolism program of the National Institutes of Health
  • NEI NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of General Medical Sciences
  • National Eye Institute

Zitieren

APA

Cleveland, K. H., Lee, K. S., Ponnalagu, D., Vicente, J. J., Parker, E. D., Lee, J. Y. E., Wordeman, L., & Scott, J. D. (2026). The β 2 ‐adrenoceptor agonist formoterol attenuates hallmarks of adrenal Cushing's syndrome. British Journal of Pharmacology, 183(11), 3129-3145. https://doi.org/10.1111/bph.70370

Vancouver

Cleveland KH, Lee KS, Ponnalagu D, Vicente JJ, Parker ED, Lee JYE, et al. The β 2 ‐adrenoceptor agonist formoterol attenuates hallmarks of adrenal Cushing's syndrome. British Journal of Pharmacology. 2026;183(11):3129-3145. doi:10.1111/bph.70370

BibTeX
@article{Cleveland2026,
  author = {Cleveland, Kristan H and Lee, Kyung-Soon and Ponnalagu, Devasena and Vicente, Juan Jesus and Parker, Edward D and Lee, Ji Yae Eunice and Wordeman, Linda and Scott, John D},
  title = {The β 2 ‐adrenoceptor agonist formoterol attenuates hallmarks of adrenal Cushing's syndrome},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {11},
  pages = {3129--3145},
  doi = {10.1111/bph.70370}
}
Kostenlos starten →